GLP-1 Evidence

Outcomes

Do GLP-1 drugs protect your heart?

SELECT found a 20% reduction in major cardiovascular events in people with obesity and existing heart disease but no diabetes. That result changed the category.

Updated 3 min read 16 citations Evidence strength 5/5

Human insulin pen of 100 units per millilitre laid on a yellow background
Wesalius · CC BY 4.0 · Wikimedia Commons

The diabetes evidence came first

GLP-1 agonists were licensed for type 2 diabetes long before obesity, and regulators required cardiovascular safety trials. Those trials did not merely show safety — they showed benefit. Pooled analyses across the programme found consistent reductions in major adverse cardiovascular events, cardiovascular death and kidney outcomes, in the region of 12-14% relative risk reduction for MACE [5][6]. REWIND extended the finding to a population with lower baseline cardiovascular risk [8].

Cardiovascular benefit in type 2 diabetes

SELECT: the trial that changed the framing

SELECT enrolled adults with overweight or obesity and established cardiovascular disease but without diabetes, and randomised them to semaglutide 2.4 mg or placebo for around four years. It found roughly a 20% reduction in the primary composite of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke.

The subsequent meta-analytic work incorporating SELECT confirms the direction and magnitude [1]. A pre-specified analysis in the heart failure subgroup found benefit there too [7].

Why it mattered: it decoupled the cardiovascular benefit from glycaemic control. Whatever is driving the event reduction, it is not simply "better diabetes management" — because these participants did not have diabetes.

How much is the weight loss doing?

This is the genuinely open question. Candidate explanations include weight loss itself, blood pressure reduction, direct anti-inflammatory effects on the vessel wall, and improved kidney function. The timing of divergence in the event curves has been used to argue for a direct effect beyond weight, but the trials were not designed to separate these and the honest answer is that the mechanism is unresolved.

Kidneys

The kidney findings have strengthened considerably. Pooled analysis in populations with established chronic kidney disease shows benefit on both kidney and cardiovascular endpoints [2], consistent with the earlier class-wide meta-analyses [5]. Tirzepatide showed kidney benefit against insulin glargine in SURPASS-4. There is more detail on the non-weight uses page.

Combining with SGLT2 inhibitors

A meta-analysis using SMART methodology examined SGLT2 inhibitors with and without GLP-1 agonists and found the benefits are not redundant [3]. For people with type 2 diabetes and cardiovascular or kidney disease, the two classes together are increasingly the standard rather than a choice between them.

The tirzepatide picture

Tirzepatide has a pre-specified meta-analysis showing no cardiovascular harm signal [4] and a direct comparison against dulaglutide reporting cardiovascular outcomes in type 2 diabetes [9]. It does not yet have a SELECT-equivalent — a dedicated outcome trial in a non-diabetic obese population — which is the main reason semaglutide retains an evidential edge on this specific endpoint despite losing on weight loss.

Common questions

Should I take this purely for heart protection?
That is a clinical decision, but SELECT is the trial your doctor will be reasoning from if you have obesity plus established cardiovascular disease. It is a licensed indication in several jurisdictions on the strength of it.
Does the benefit disappear if I stop?
Events prevented while on treatment stay prevented. Whether ongoing protection persists after discontinuation has not been tested — and given that weight and risk factors revert, as covered on the stopping page, there is no reason to assume it does.
Is a 20% relative reduction large?
It is comparable to what statins achieve in secondary prevention, which is the usual benchmark. As always, the absolute benefit depends on your baseline risk.
Do all GLP-1 drugs share this?
The class effect in diabetes is well supported [5][6]. The extension to non-diabetic obesity currently rests on semaglutide specifically.
Insulin injection pen photographed lengthwise against a yellow background
Wesalius · CC BY 4.0 · Wikimedia Commons
The evidence behind this page A stacked bar showing the composition of the 16 publications cited on this page by study type. 1141meta-analysis (11)randomised trial (4)other (1)
16 publications, 2018–2026. That is a mix with both trials and syntheses in it, which is the position from which a claim about cause is reasonable. Source: this page’s own citation list, below.

References

Every citation below links to the original peer-reviewed record on PubMed or via DOI. Nothing here is a substitute for medical advice.

  1. Exploratory Cardiovascular Risk Modeling of Orforglipron Using the PREVENT Equations Compared with the Pooled Cohort Equations: A Post-Hoc Analysis from a Systematic Review and Meta-analysis Alper A, Fagin A, Karthikeyan A, et al. · High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2026 · Meta-analysis DOIPubMed 42458197
  2. The Impact of GLP-1-Based Therapies on Cardiovascular Outcomes in Type 2 Diabetes: A Comprehensive Systematic Review and Network Meta-Analysis Chuang SM, Liu SC, Chien KL, et al. · Diabetes, obesity & metabolism · 2026 · Meta-analysis DOIPubMed 42219271Full text
  3. Comparative efficacy of tirzepatide and glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes: a systematic review and network meta-analysis Shokravi A, Seth J, Mancini GBJ · Cardiovascular diabetology · 2026 · Meta-analysis DOIPubMed 41761267Full text
  4. Semaglutide effects on safety and cardiovascular outcomes in patients with overweight or obesity: a systematic review and meta-analysis Cleto AS, Schirlo JM, Beltrame M, et al. · International journal of obesity (2005) · 2025 · Meta-analysis DOIPubMed 39396098
  5. Kidney and Cardiovascular Outcomes Among Patients With CKD Receiving GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomized Trials Chen JY, Hsu TW, Liu JH, et al. · American journal of kidney diseases : the official journal of the National Kidney Foundation · 2025 · Meta-analysis DOIPubMed 39863261
  6. Cardiovascular and renal outcomes of dual combination therapies with glucagon-like peptide-1 receptor agonists and sodium-glucose transport protein 2 inhibitors: a systematic review and meta-analysis Shokravi A, Seth J, Mancini GBJ · Cardiovascular diabetology · 2025 · Meta-analysis DOIPubMed 41029853Full text
  7. Evaluation of three mechanisms of action (SGLT2 inhibitors, GLP-1 receptor agonists, and sulfonylureas) in treating type 2 diabetes with heart failure: a systematic review and network meta-analysis of RCTs Gao H, Wei Q, Zou A, et al. · Frontiers in endocrinology · 2025 · Meta-analysis DOIPubMed 40556828Full text
  8. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials Apperloo EM, Neuen BL, Fletcher RA, et al. · The lancet. Diabetes & endocrinology · 2024 · Meta-analysis DOIPubMed 38991584
  9. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis Sattar N, McGuire DK, Pavo I, et al. · Nature medicine · 2022 · Meta-analysis DOIPubMed 35210595Full text
  10. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials Kristensen SL, Rørth R, Jhund PS, et al. · The lancet. Diabetes & endocrinology · 2019 · Meta-analysis DOIPubMed 31422062
  11. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis Bethel MA, Patel RA, Merrill P, et al. · The lancet. Diabetes & endocrinology · 2018 · Meta-analysis DOIPubMed 29221659
  12. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial Deanfield J, Verma S, Scirica BM, et al. · Lancet (London, England) · 2024 · Randomised controlled trial DOIPubMed 39181597
  13. Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure Marso SP, Baeres FMM, Bain SC, et al. · Journal of the American College of Cardiology · 2020 · Randomised controlled trial DOIPubMed 32164886
  14. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial Gerstein HC, Colhoun HM, Dagenais GR, et al. · Lancet (London, England) · 2019 · Randomised controlled trial DOIPubMed 31189511
  15. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics Nicholls SJ, Bhatt DL, Buse JB, et al. · American heart journal · 2024 · Clinical trial DOIPubMed 37758044
  16. New Drug: Tirzepatide (Mounjaro(™)) Gettman L · The Senior care pharmacist · 2023 · Journal article DOIPubMed 36751934